Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) recovered 15.92% of its value since hitting low of $11.15. The recent move of -2.51% drop pushed the stock to close at $11.65 when trading ended on Jul. 14, 2017. At recent session, the prices were hovering between $11.2 and $12.8. This company shares are 208.07% off its target price of $35.89 and the current market capitalization stands at $584.83M. The recent change has given its price a -29.32% deficit over SMA 50 and -68.06% deficit over its 52-week high. The stock witnessed -31.67% declines, -46.31% declines and -44.12% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ALDR’s volatility during a week at 9.97% and during a month it has been found around 8.44%.Alder Biopharmaceuticals, Inc. (ALDR) Top Holders
Institutional investors currently hold around $633 million or 73.8% in ALDR stock. Look at its top three institutional owners. Fmr Llc owns $89.35 million in Alder Biopharmaceuticals, Inc., which represents roughly 15.28% of the company’s market cap and approximately 14.12% of the institutional ownership. Similar statistics are true for the second largest owner, Janus Capital Management Llc, which owns 5,167,085 shares of the stock are valued at $61.75 million. The third largest holder is Blackrock Inc., which currently holds $47.28 million worth of this stock and that ownership represents nearly 8.08% of its market capitalization.Alder Biopharmaceuticals, Inc. 13F Filings
At the end of March 2017 reporting period, 71 institutional holders increased their position in Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) by some 4,115,151 shares, 61 decreased positions by 4,592,400 and 25 held positions by 44,272,860. That puts total institutional holdings at 52,980,411 shares, according to SEC filings. The stock grabbed 19 new institutional investments totaling 868,765 shares while 14 institutional investors sold out their entire positions totaling 973,525 shares.Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Insider Trades
Multiple company employees have indulged in significant insider trading. Alder Biopharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Sr. VP Translational Medicine Smith Jeffrey T L has sold 585 shares of Alder Biopharmaceuticals, Inc. (ALDR) in trading session dated Jun. 20, 2017. These shares are worth $11,700 and were traded at $20 each. The SEC filing shows that Schatzman Randall C performed a sale of 30,000 shares. The President and CEO disposed these shares by way of transaction on Feb. 09, 2017. The company’s shares were given away at $25.03 per share worth to an income of some $750,900 on account of Schatzman Randall C.
Chief Business Officer, Litton Mark James, sold 1,498 common shares of Alder Biopharmaceuticals, Inc. (ALDR) in the open market. In a transaction dated Jan. 18, 2017, the shares were put up for sale at an average price of $23.1, raking in a sum of $34,604. After this sale, 125,932 common shares of ALDR are directly owned by the insider, with total stake valued at $1,467,108.
In the transaction dated Jan. 09, 2017, the great number of shares disposed came courtesy the Chief Business Officer; Litton Mark James disposed a total of 9,516 shares at an average price of $23.01, amounting to approximately $218,963. The insider now directly owns 125,932 shares worth $1,467,108.Alder Biopharmaceuticals, Inc. (ALDR) Analyst Guide
Several analysts have released their opinion on Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR), with 6 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 1 strong sell ratings, collectively assigning a 1.63 average brokerage recommendation.